By Myles Starr
The 2022 mpox outbreak put people with HIV (PWH) at higher risk for poor outcomes and severe disease than the general population. In response to a lack of drugs proven effective against the virus, the FDA approved the antiviral medicine tecovirimat (Tpoxx, SIGA Technologies) to treat the disease.
Data from a retrospective cohort study presented at CROI 2024, in Denver, suggest the drug was effective in helping PWH arrest the progression of mpox infections.